Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. retindr

RetinDR SIGNED

RetinDR: The first topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RetinDR project word cloud

Explore the words cloud of the RetinDR project. It provides you a very rough idea of what is the project "RetinDR" about.

stages    grow    final    15    diabetic    commercialization    seeing    prevents    industrial    115    aging    topical    repurposing    diabetes    co    commercialisation    suffer    disease    limited    progresses    drops    licensing    retindr    forecast    treats    worldwide    retinopathy    pharmaceutical    55m    98    52m    successful    double    substance    hypertension    agreements    receptor    cagr    floaters    aged    22    company    5    feasibility    wacc    markets    spots    1    share    3    ebitda    blindness    people    usually    treatments    million    accounted    completion    pulmonary    jobs    arterial    aggressive    eye    drug    peripheral    93    endothelin    neurodegeneration    royalties    retinal    till    irr    outside    21m    vision    formulation    plan    symptoms    effectiveness    market    months    adults    business    81b    antagonist    estimate    model    2016    receive    treatment    revenues    blurred    reading    quite    europeans    considering    ophthalmic    npv    sme    equalling    mix    sales    parent    difficulty    prevention    2025    indicated    medical    dr    bosentan    strategic    global   

Project "RetinDR" data sheet

The following table provides information about the project.

Coordinator		 RETINSET SL 

Organization address
address: AMPOSTA 20
city: SANT CUGAT DEL VALLES
postcode: 8174
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RETINSET SL ES (SANT CUGAT DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults. About 93 million people worldwide and 3%-4.1% of Europeans suffer this disease. The early stages of DR usually have no symptoms, however when the disease progresses it affects vision: blurred vision, seeing double, difficulty reading, spots or floaters in the field of vision, and loss of peripheral vision. Current treatments are quite aggressive, are only indicated in advanced stages of the disease, have significant side effects and their effectiveness is limited. RetinDR is a topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging. The pharmaceutical development of RetinDR is based on the repurposing of the drug substance bosentan (endothelin receptor antagonist, currently indicated for the pulmonary arterial hypertension treatment) for the prevention and treatment of DR.

The global DR market accounted for $5.81B in 2016 and is forecast to grow at 6.3%. CAGR till 2025. We estimate a market share of 0.115% 5 years after commercialisation, equalling revenues of 52M€. Our main business model will focus on sales and distribution of RetinDR in Europe through a distribution agreement with the parent company Medical Mix S.L. and co-development or licensing agreements with strategic industrial partners in markets outside of Europe where we will receive royalties.

With this model and the successful completion of the SME Phase 1 and 2 we estimate an EBITDA of over 55M€ in 5 years after commercialization an IRR of 98% and NPV of over 21M€ considering a WACC of 15%, creating 22 new jobs by 2025. The Feasibility Study for this project will take 6 months and focus on an in-depth market study, technical testing and the development of final business plan to take us to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RETINDR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RETINDR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More